The company said it will initially focus on commercializing MediScan in Asia and more specifically in China. Median plans to collaborate with Chinese investor and partner Furui to help position MediScan as the reference medical device for major programs dedicated to cancer screening, detection, diagnosis, and monitoring in China. In addition, Median will also focus on the European market by leveraging its legacy hospital-based customers who were early adopters of Median's previous Lesion Management Solution software, according to the vendor.

Future releases of MediScan will include new technology based on artificial intelligence, cloud computing, and big-data analytics, according to the vendor.